![Grégoire Pierre Prevost](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Grégoire Pierre Prevost worked as Director of Oncology Translational Research at Ipsen SA, Director of Preclinical Development at iTeos Therapeutics SA, and Chief Development Officer at InteRNA Technologies BV.
He holds a doctorate degree from Université François-Rabelais de Tours.
| Sociétés | Poste | Fin |
|---|---|---|
iTeos Therapeutics SA
 iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology Engages in the discovery of immunomodulators for cancer therapy | Corporate Officer/Principal | - |
| IPSEN | Corporate Officer/Principal | - |
InteRNA Technologies BV
 InteRNA Technologies BV BiotechnologyHealth Technology Engages in the development of novel breakthrough therapies in chronic disorders | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 4 |
|---|---|
Ipsen SA
 Ipsen SA Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Université François-Rabelais de Tours
 Université François-Rabelais de Tours Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology Engages in the development of novel breakthrough therapies in chronic disorders | Health Technology |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology Engages in the discovery of immunomodulators for cancer therapy | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
